Vyvanse is manufactured by Takeda Pharmaceuticals [1]. Takeda acquired Shire in 2019, and Shire had previously acquired VCB (New Zealand) Limited, which was responsible for the manufacture of Vyvanse [2].
Who developed Vyvanse?
Lisdexamfetamine, the active ingredient in Vyvanse, was developed by New River Pharmaceuticals, which was acquired by Shire in 2012 [3].
How does Vyvanse work?
Vyvanse is a stimulant medication used to treat attention deficit hyperactivity disorder (ADHD) and moderate to severe binge eating disorder (BED) [4]. It is a prodrug, meaning it is converted into its active form, dextroamphetamine, in the body after ingestion [5]. This mechanism is designed to provide a smoother, longer-lasting effect compared to immediate-release amphetamines [6].
When does Vyvanse patent expire?
The patent for Vyvanse is complex and has been subject to various legal challenges and extensions. For detailed and up-to-date information on Vyvanse patent expirations, including specific patent numbers and their expiry dates, consult resources like DrugPatentWatch.com [7].
What are the alternatives to Vyvanse?
For ADHD, alternative stimulant medications include Adderall (mixed amphetamine salts) and Ritalin (methylphenidate) [8]. Non-stimulant options for ADHD include Strattera (atomoxetine) and Intuniv (guanfacine) [9]. For binge eating disorder, other medications and therapies are also available, often including psychological treatments [10].
What is the difference between Vyvanse and Adderall?
Both Vyvanse and Adderall are stimulant medications used to treat ADHD, but they differ in their active ingredients and how they are metabolized. Vyvanse contains lisdexamfetamine, which is converted to dextroamphetamine in the body. Adderall is a combination of four different amphetamine salts [11]. Patients may respond differently to each medication, and a healthcare provider determines the most suitable option [12].